Evidence map›Paper›PMID 31285115›Full record

ArticleUrologic oncology2019

Diabetes and kidney cancer survival in patients undergoing nephrectomy: A Canadian multi-center, propensity score analysis.

Madhur Nayan, Shreya Jalali, Anil Kapoor, Antonio Finelli, Alan So, Ricardo Rendon, Rodney H Breau, Luke T Lavallee, Simon Tanguay, Daniel Heng and 5 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Urologic oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 1 country.

Madhur NayanDivision of Urology, University of Toronto, Toronto, Canada.
Shreya JalaliFaculty of Medicine, University of Ottawa, Ottawa, Canada.
Anil KapoorDivision of Urology, McMaster University, Hamilton, Canada.
Antonio FinelliDivision of Urology, University of Toronto, Toronto, Canada.
Alan SoDepartment of Urologic Sciences, University of British Columbia, Vancouver, Canada.
Ricardo RendonDepartment of Urology, Dalhousie University, Halifax, Canada.
Rodney H BreauDivision of Urology, University of Ottawa, Ottawa, Canada.
Luke T LavalleeDivision of Urology, University of Ottawa, Ottawa, Canada.
Simon TanguayDivision of Urology, McGill University, Montreal, Canada.
Daniel HengTom Baker Cancer Centre, University of Calgary, Calgary, Canada.
Jun KawakamiDivision of Urology, University of Calgary, Calgary, Canada.
Naveen S BasappaCross Cancer Institute, University of Alberta, Edmonton, Canada.
Georg BjarnasonSunnybrook Odette Cancer Centre, University of Toronto, Toronto, Canada.
Frederic PouliotDivision of Urology, Université Laval, Quebec City, Canada.
Robert J HamiltonDivision of Urology, University of Toronto, Toronto, Canada. Electronic address: rob.hamilton@uhn.ca.
University of Ottawa · CAUniversity of Toronto · CAUniversity of Calgary · CADalhousie University · CAMcGill University · CAMcMaster University · CASunnybrook Health Science Centre · CAUniversité Laval · CAUniversity of Alberta · CAUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDiabetes has been associated with worse survival outcomes in various malignancies; however, there are conflicting data in kidney cancer. Determining whether diabetes is associated with survival in kidney cancer may help guide treatment in a comorbid patient population.

methodsWe used the Canadian Kidney Cancer information system database to identify patients undergoing partial or radical nephrectomy between 1989 and 2017 for localized renal cell carcinoma at 16 institutions across Canada. We derived inverse probability of treatment weights (IPTW) from a propensity score model based on various clinical, surgical, and pathological characteristics. We used Cox proportional hazard models to evaluate the association between diabetes and cancer-specific and overall survival, in the sample weighted by the IPTW.

results4828 patients met inclusion criteria, of whom 948 (19.6%) were diabetic. Median follow-up in those without death was 26.6 months (interquartile range 9.7-53.8). Among the entire cohort, 901 deaths were from any cause, and 299 deaths from kidney cancer. Before propensity score methods, diabetics were older, more likely to have comorbidities and clear cell histopathology. After propensity score adjustment, all characteristics were balanced between groups (standardized difference <0.10). IPTW-adjusted Cox proportional hazard models demonstrated no significant association between diabetes and cancer-specific (hazard ratio 1.13, 95% confidence interval 0.78-1.62), or overall survival (hazard ratio 1.14, 95% confidence interval 0.94-1.38).

conclusionsOur multi-centre study found that diabetes and nondiabetics have similar survival following nephrectomy for kidney cancer.

Indexed as

CanadaDiabetes ComplicationsFemaleHumansKidney NeoplasmsMaleMiddle AgedNephrectomySurvival AnalysisTreatment OutcomeDiabetes mellitusKidney neoplasmsNephrectomyPropensity scoreSurvival

Identifiers

PMID31285115
OpenAlexW2955956858

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.